NEW YORK--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO) continues to lead the market with its cloud-based clinical development platform through a new customer commitment from Mesoblast Limited, a world leader in developing biologic products for the broad field of regenerative medicine. Mesoblast will implement Medidata Rave®, including Rave Safety Gateway and Rave Targeted SDV, and Medidata Coder™ across its clinical studies to support the development of treatments based on its proprietary adult stem cell technology.
